NCT01013051

Brief Summary

Background: Gastric bypass is the most commonly performed type of bariatric (obesity) surgery, has dramatically increased in popularity and is now considered to be preferred treatments in severely obese patients that fail non-surgical therapy - particularly in patients with type 2 diabetes. Drug malabsorption is a potential concern post-gastric bypass because intestinal length is reduced. Purpose: The purpose of this controlled, pharmacokinetic study is to determine whether the absorption of a single dose of metformin, the first line drug treatment in patients with type 2 diabetes, is significantly reduced after gastric bypass. Methods: A single dose of standard release metformin 1000 mg will be administered to patients who have undergone gastric bypass and to patients who have not received surgery but are on the wait list (wait-listed controls). Blood sampling and urine sampling will occur in standardized fashion over the ensuing 24 hours to measure and compare the absorption of metformin between study arms. 34 patients total will be recruited. Significance: Following completion of this study, we will better understand how gastric bypass affects metformin absorption. Ultimately, this information will help to ensure that this patient population is receiving optimal doses of this important drug treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
34

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2009

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2009

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

November 12, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 13, 2009

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2010

Completed
Last Updated

March 3, 2011

Status Verified

March 1, 2011

First QC Date

November 12, 2009

Last Update Submit

March 2, 2011

Conditions

Keywords

obesitygastric bypassmetforminpharmacokineticsabsorption

Outcome Measures

Primary Outcomes (1)

  • Area-under-the-curve of metformin absorption (0-infinity)

    cross-sectional

Secondary Outcomes (5)

  • AUC (0-24h)

    cross-sectional

  • tmax

    cross-sectional

  • cmax

    cross-sectional

  • AUC glucose (0-8h)

    cross-sectional

  • bioavailability of metformin (urine metformin concentration from 0-infinity)

    cross-sectional

Study Arms (2)

Post Gastric Bypass

Obese Controls

age, BMI, gender matched

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Post gastric bypass and obese controls 1. Male and Female 2. 18 - 60 years old 3. ≥ 3 months post-RYGB surgery or wait listed for bariatric surgery 4. Able to provide written informed consent.

You may qualify if:

  • Patients living within and around Edmonton that have been referred to the Alberta Health Services Weight Wise Program

You may not qualify if:

  • Undergone or undergoing revision of a previous bariatric procedure
  • Any major post-operative gastrointestinal complications, such as an anastomotic leak, outlet obstruction or persistent vomiting
  • Currently on metformin therapy
  • Any contraindications to metformin therapy such as:
  • allergy to the drug
  • chronic metabolic acidosis
  • history of lactic acidosis
  • liver failure or baseline liver enzymes higher than 3-fold above the upper limit of normal
  • congestive heart failure
  • renal failure (glomerular filtration rate \< 60 ml/min)
  • alcoholism
  • acute illness
  • fatty liver disease
  • Pregnant or nursing
  • Not taking furosemide or nifedipine (both drugs may increase metformin absorption by 15-20%)the day of visit 2.
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Alberta Hospital Clinical Investigation Unity

Edmonton, Alberta, T6G2B7, Canada

Location

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Raj Padwal, MD

    University of Alberta

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 12, 2009

First Posted

November 13, 2009

Study Start

September 1, 2009

Study Completion

December 1, 2010

Last Updated

March 3, 2011

Record last verified: 2011-03

Locations